Alla studier
RekryteringFAS1, FAS2INTERVENTIONELL

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

This research study is investigating a new oral medicine called repotrectinib (also known as TPX-0005) for people with advanced solid cancers. These are cancers that have spread or are difficult to treat with standard methods. The study is particularly looking at cancers that have specific genetic changes called ALK, ROS1, or NTRK rearrangements. It has two main parts: Phase 1 is about finding the right dose of the new drug, how safe it is, and what side effects it might cause. Phase 2 then looks at how effective repotrectinib is in making tumours shrink or stopping them from growing in different types of cancer with these gene changes, especially ROS1 and NTRK. Researchers will also check how long the positive effects last and how quality of life is affected.

Överblick

Status
Rekrytering
Fas
FAS1, FAS2
Sponsor
Turning Point Therapeutics, Inc.
Inskrivningsmål
500
Starta
07 Mar 2017
Beräknad slutförande
29 feb 2028

Vad handlar denna studie om?

This clinical trial is designed to investigate a new medication called repotrectinib (also known as TPX-0005). Researchers are hoping this new drug could be a helpful treatment option for people who have advanced solid cancers. 'Advanced' means the cancer has either spread to other parts of the body (metastatic) or is in a later stage locally.

The study is focusing on cancers that have a specific type of genetic change, often called a gene 'rearrangement' or 'fusion'. These changes involve genes named ALK, ROS1, or NTRK1-3. These gene changes can sometimes make cancer cells grow and spread. Medicines that target these specific changes are often called 'targeted therapies' and can sometimes be very effective because they specifically attack the cancer cells while leaving healthy cells alone as much as possible.

The study has two main parts, called phases. Phase 1 is about finding the best dose of repotrectinib that can be given safely without causing too many side effects. It also helps researchers understand how the medicine works in the body and if there are any early benefits. Phase 2 then takes that information and looks more closely at how well the drug works in shrinking tumours or stopping them from growing in different groups of people whose cancers have these specific ROS1 or NTRK gene changes. They will also look at how long any positive effects last and how the treatment affects a person's overall health and wellbeing.

Viktiga punkter

  • This study is testing a new oral drug called repotrectinib for advanced solid cancers.
  • It focuses on cancers with specific genetic changes (ALK, ROS1, or NTRK).
  • Phase 1 finds the safest dose, and Phase 2 checks how well it works.
  • Participants take capsules and have regular check-ups and scans.
  • This is an experimental treatment, and its benefits are not guaranteed.

Vem kan vara berättigad?

To be considered for this study, you would generally need to have an advanced solid cancer that has specific genetic changes involving the ALK, ROS1, or NTRK genes. Doctors will use special tests to check for these changes. Your overall health and how well you can carry out daily activities will also be important, and you'll need to be well enough to take the study medication by mouth.

There are also specific medical requirements your doctor will check, such as your blood test results and how certain organs like your liver and kidneys are working. You and your doctor will need to review all the detailed eligibility criteria to see if this study could be a suitable option for you. The study includes people from 12 years of age and older.

For Phase 2, the focus is specifically on cancers with ROS1 or NTRK gene changes. There are several different groups within Phase 2 depending on whether you've had previous treatments for your cancer, such as targeted therapies or chemotherapy, and how those treatments worked.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Do I have an advanced solid cancer diagnosis?
  2. Do tests show my cancer has an ALK, ROS1, or NTRK gene change?
  3. Am I generally well enough to participate in a clinical study?
  4. Am I able to swallow capsules whole?
  5. Have I discussed my previous cancer treatments with my doctor?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you'll be given the study drug, repotrectinib, as a capsule to take by mouth. The study involves regular visits to the hospital or clinic for assessments. These assessments will include blood tests, scans (like CT or MRI) to check your cancer, and check-ups with the doctor to see how you are feeling and if you have any side effects.

How often you visit and for how long depends on which part of the study you are in and how you respond to the treatment. There will be initial frequent visits, which may become less frequent over time. The total duration of your participation will depend on how your cancer responds to the treatment and your overall health, but it could last for many months or even longer if the treatment is helping.

Potentiella risker och fördelar

Like all medicines, repotrectinib might have side effects, which the study team will monitor closely. These will be explained to you in detail. There is no guarantee that repotrectinib will help your cancer, but participating could provide valuable information that helps others in the future. You always have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (165)

  • Local Institution - 2129
    Verifierat postnummer
    Duarte, USA· Avslutad
  • Local Institution - 2120
    Verifierat postnummer
    Glendale, USA· Avslutad
  • Local Institution - 2136
    Verifierat postnummer
    La Jolla, USA· Återkallad
  • Local Institution - 2114
    Verifierat postnummer
    La Jolla, USA· Avslutad
  • Local Institution - 2121
    Verifierat postnummer
    Long Beach, USA· Avslutad
  • Local Institution - 1001
    Verifierat postnummer
    Orange, USA· Avslutad
  • Local Institution - 2101
    Verifierat postnummer
    Orange, USA· Avslutad
  • St Joseph Heritage Healthcare
    Verifierat postnummer
    Santa Rosa, United States· Rekrytering
  • Local Institution - 1003
    Verifierat postnummer
    Aurora, USA· Avslutad
  • Local Institution - 2103
    Verifierat postnummer
    Aurora, USA· Avslutad
  • Local Institution - 2106
    Verifierat postnummer
    Washington D.C., USA· Avslutad
  • Local Institution - 2110
    Verifierat postnummer
    Washington D.C., USA· Avslutad

Vanliga frågor

What is repotrectinib and how is it given?

Repotrectinib is a new experimental drug in the form of a capsule that you take by mouth.

Vilka typer av cancer är denna studie för?

It's for advanced solid cancers that have specific genetic changes in the ALK, ROS1, or NTRK genes.

What does 'gene rearrangement' mean?

It's a change in your cancer's genetic material that can make the cancer grow. This drug aims to target that specific change.

Will I know if the drug is working?

The study team will use scans and tests to check how your cancer responds to the treatment.

Kan jag sluta delta i studien om jag vill?

Yes, you can choose to stop participating at any time without it affecting your medical care.

Hur du får reda på mer

BMS Kliniska Prövningar Kontaktcenter www.BMSClinicalTrials.com

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study of Repotrectinib (TPX-0005) in Patients With Advance…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.